Oxytetracycline in the treatment of ocular rosacea: A double-blind trial

Abstract

Thirty-five patients with ocular rosacea were admitted to a trial of systemic oxytetracycline, 250 mg b.d. for 6 weeks. Oxytetracycline produced a significantly higher number of remissions than the placebo, 11/35. With repeated or continouus treatment 19/35 patients achieved a sustained remission of 8 months. There were no side effects. The nonspecific signs of ocular rosacea responded well to the treatment, but no permanent change in the conjunctival or corneal vascularisation occurred.